Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) COO Acquires $250,000.20 in Stock

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) COO Denise P. Carter acquired 555,556 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The shares were bought at an average price of $0.45 per share, for a total transaction of $250,000.20. Following the completion of the acquisition, the chief operating officer now owns 602,648 shares of the company’s stock, valued at $271,191.60. This trade represents a 1,179.72 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Quoin Pharmaceuticals Trading Down 1.6 %

Shares of NASDAQ QNRX opened at $0.55 on Monday. The company has a fifty day moving average price of $0.68 and a 200 day moving average price of $0.63. The firm has a market cap of $2.78 million, a PE ratio of -0.14 and a beta of 1.79. Quoin Pharmaceuticals, Ltd. has a 1-year low of $0.43 and a 1-year high of $6.18.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.